- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03573115
Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Epiduo is a prescription gel that combines adapalene and benzoyl peroxide, two active substances for the external treatment of acne. Adapalene is a substance that resembles A-vitamin acid, which dissolves and prevents clog formation in the sebaceous glands. Benzoyl peroxide works by reducing the amount of bacteria while dissolving the clogs in the sebaceous glands. Epiduo is the only antibiotic-free combination for the treatment of acne.
Reflectance Confocal Microscopy (RCM) and Optical Coherence Tomography (OCT) are non-invasive imaging technologies allowing for imaging of the upper skin layers. Gold microparticles have been shown to have a contrast effect on the images. In addition to the contrast effect on images, gold microparticles have proven to be effective in the treatment of skin disease acne. The treatment with gold microparticles uses a combination of the gold microparticles and a laser. The microparticles consist of very small particles of silica, surrounded by a shell of gold. These two components of the microparticles are selected from their way of absorbing light from a laser. The particles absorb the light from the laser and are thus heated. The surrounding skin can not absorb the light and therefore will maintain its normal temperature.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2400
- Bispebjerg Hospital, Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a clinical diagnosis of acne vulgaris, IGA score 1-3
- 18-45 years of age at baseline
- Legally competent, able to give verbal and written consent
- Communicate in Danish verbally as well as in writing
- Fitzpatrick skin phototype I-III
- Subjects in good general health, willing to participate and able to give informed consent, and can comply with protocol requirements
- Female subjects of childbearing potential (1) must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment
- Female subjects must use one of following contraceptive techniques to be included in the study: intrauterine device (IUD) or hormonal contraception (birth control pills, birth control patch, birth control vaginal ring, birth control shot or birth control implant) (1) Female subjects are considered of childbearing potential unless they have been hysterectomized
Exclusion Criteria:
- Subjects with a known allergy to gold microparticles or Epiduo®
- Individuals with other skin disease than acne or skin lesions in the area of research interest
- Subjects with tattoo in the treatment area which may interfere with or confound evaluation of the study
- Subjects with moderate-severe to severe acne (IGA 4-5 and those presenting with either cysts or nodules) requiring continuation of systemic treatment during the study period
- Subjects with a history of keloids which is deemed clinically relevant in the opinion of the investigator
- Subjects with active skin disease or excessive scarring that, in the opinion of the investigator, would impact the ability to administer the gold microparticles or use of OCT/RCM in the areas
- Pregnant and lactating women
- Subjects who have received investigational drugs or were treated with investigational devices within 30 days prior to baseline
- Treatment with oral retinoid 3 months prior to baseline
- Treatment with systemic antibiotics 4 weeks prior to baseline
- Topical retinoids, topical antibiotics or topical products with benzoyl peroxide 4 weeks prior to baseline
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Acne patients
|
Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gold microparticle delivery after 6 weeks of pretreatment evaluated by RCM
Time Frame: baseline and after 6 weeks of study
|
Quantitative evaluation of fraction of follicles with gold microparticles at baseline and after 6 weeks of study.
Change in fraction of follicles with gold will be assessed.
|
baseline and after 6 weeks of study
|
Change in gold microparticle delivery after 6 weeks of pretreatment evaluated by OCT
Time Frame: baseline and after 6 weeks of study
|
Quantitative evaluation of depth of gold in hair follicles at baseline and after 6 weeks of pretreatment, measured in um.
Change in depth will be assessed.
|
baseline and after 6 weeks of study
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Dermatologic Agents
- Benzoyl Peroxide
- Adapalene
Other Study ID Numbers
- EudraCT: 2017-002975-25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Adapalene-Benzoyl Peroxide Gel 0.1-2.5%
-
Galderma R&DCompleted
-
Galderma R&DCompleted
-
Galderma R&DCompletedP Acnes ColonizationUnited States
-
Galderma R&DCompleted
-
Galderma R&DCompletedAcneUnited States, Canada, Puerto Rico
-
Mahidol UniversityWithdrawnFoot Dermatoses | Benzoyl PeroxideThailand
-
Galderma R&DCompletedAcne VulgarisUnited States
-
Taro Pharmaceuticals USACompleted
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedAcne VulgarisUnited States